Knackstedt Rebecca W, Knackstedt Thomas, Gastman Brian
Cleveland Clinic Foundation, Department of Plastic Surgery, Cleveland, Ohio.
Cleveland Clinic Foundation, Department of Dermatology, Cleveland, Ohio.
J Surg Res. 2018 Dec;232:365-368. doi: 10.1016/j.jss.2018.06.070. Epub 2018 Jul 18.
Merkel cell carcinoma (MCC) is a relatively rare skin cancer with high rates of regional lymph node involvement and metastatic spread. National Comprehensive Cancer Network guidelines recommend sentinel lymph node biopsy (SLNB) for staging purposes. The goal of this study is to report our experience utilizing indocyanine green (ICG) fluorescence-based technology to aid in SLNB detection in MCC.
Consecutive MCC patients who underwent SLNB with radioisotope lymphoscintigraphy, with intraoperative handheld gamma probe, and ICG-based fluorescence imaging from 2012 to 2017 were prospectively studied (Cohort A). A group of historical controls that underwent SLNB for MCC with radioisotope lymphoscintigraphy and vital blue dye (VBD) (lymphazurin or methylene blue dye) was also analyzed (Cohort B).
Twenty-four consecutive patients underwent SLNB with lymphoscintigraphy and ICG-based fluorescence and 11 controls underwent SLNB with lymphoscintigraphy and VBD. The localization rate by node with VBD was 63.6% and ICG-based fluorescence was 94.8%. For two patients, a positive sentinel lymph node (SLN) was detected only by ICG-based fluorescence and the nodes were not detected by gamma probe and one patient's only positive node was identified via ICG fluorescence only. VBD or gamma probe did not identify any unique positive SLNs in either cohort B or either cohort, respectively.
In this study, we indicate that ICG-based fluorescence is not only feasible to augment SLN identification, but it has a higher node localization rate as compared to blue dye and it was able to identify positive SLNs otherwise missed by gamma probe. This study suggests the importance of utilizing two modalities to augment SLN identification and that ICG-based fluorescence may be able to identify nodes that would have been otherwise missed by gamma probe. We will continue to follow these patients and enroll more patients in this prospective study to further determine the role that ICG-based fluorescence has in identifying sentinel lymph nodes in MCC.
默克尔细胞癌(MCC)是一种相对罕见的皮肤癌,区域淋巴结受累和转移扩散率较高。美国国立综合癌症网络指南推荐进行前哨淋巴结活检(SLNB)以进行分期。本研究的目的是报告我们利用基于吲哚菁绿(ICG)荧光技术辅助MCC中SLNB检测的经验。
对2012年至2017年期间接受放射性同位素淋巴闪烁显像、术中手持式γ探测器以及基于ICG的荧光成像的连续MCC患者进行前瞻性研究(队列A)。还分析了一组采用放射性同位素淋巴闪烁显像和活性蓝色染料(VBD)(淋巴蓝或亚甲蓝染料)进行MCC的SLNB的历史对照(队列B)。
24例连续患者接受了淋巴闪烁显像和基于ICG的荧光的SLNB,11例对照接受了淋巴闪烁显像和VBD的SLNB。VBD的淋巴结定位率为63.6%,基于ICG的荧光为94.8%。对于两名患者,仅通过基于ICG的荧光检测到前哨淋巴结(SLN)阳性,γ探测器未检测到这些淋巴结,且一名患者仅通过ICG荧光识别出唯一的阳性淋巴结。VBD或γ探测器在队列B或任一队列中均未识别出任何独特的阳性SLN。
在本研究中,我们表明基于ICG的荧光不仅可用于增强SLN识别,而且与蓝色染料相比具有更高的淋巴结定位率,并且能够识别γ探测器遗漏的阳性SLN。本研究表明采用两种方法增强SLN识别的重要性,并且基于ICG的荧光可能能够识别γ探测器遗漏的淋巴结。我们将继续随访这些患者,并在这项前瞻性研究中纳入更多患者,以进一步确定基于ICG的荧光在识别MCC前哨淋巴结中的作用。